(Reuters) – South Africa’s Health Regulatory Authority, on Saturday, recommended the government to lift the suspension of COVID-19 vaccine administration by pharmaceutical manufacturer Johnson & Johnson (NYSE :), with conditions meet certain conditions.
The South African Health Products Authority (SAHPRA) said: “These conditions include, but are not limited to, enhanced screening and monitoring of participants at high risk of clotting disorders. “.
“Additionally, measures will be taken to ensure the safe management of any participant who develops vaccine-induced thrombocytopenia and thrombocytopenia (VITT),” the statement added.
SAHPRA said on Wednesday that it had reviewed data from local Johnson & Johnson research on vaccination of health workers and found no major safety concerns.
South Africa suspended the implementation of J&J vaccines in the “development study” on Tuesday, after US health authorities recommended suspending the use of the vaccine because of rare cases. blood clots in six vaccinated people, out of about 7 million people shot in the United States.
A US council will meet next week to discuss whether the suspension of vaccines should continue, after delaying a vote on the matter earlier this week.
Fusion Media or anyone associated with Fusion Media will not be liable in any way for loss or damage resulting from dependence on information including data, quotes, charts and buy / sell signals contained in the this site. Please be fully informed about the risks and costs associated with trading the financial markets, which is one of the riskiest investments possible.